PMID- 26749069
OWN - NLM
STAT- MEDLINE
DCOM- 20170719
LR  - 20221207
IS  - 2151-4658 (Electronic)
IS  - 2151-464X (Print)
IS  - 2151-464X (Linking)
VI  - 68
IP  - 9
DP  - 2016 Sep
TI  - Axl, Ferritin, Insulin-Like Growth Factor Binding Protein 2, and Tumor Necrosis 
      Factor Receptor Type II as Biomarkers in Systemic Lupus Erythematosus.
PG  - 1303-9
LID - 10.1002/acr.22835 [doi]
AB  - OBJECTIVE: To evaluate the performance of 4 serum protein markers for detecting 
      concurrent clinical activity in patients with systemic lupus erythematosus (SLE). 
      METHODS: Consecutive patients who fulfilled >/=4 American College of Rheumatology 
      classification criteria for SLE and healthy controls were recruited for serologic 
      testing of 4 protein markers identified by antibody-coated microarray screen, 
      namely Axl, ferritin, insulin-like growth factor binding protein 2 (IGFBP-2), and 
      tumor necrosis factor receptor type II (TNFRII). SLE disease activity was 
      assessed by the Safety of Estrogens in Lupus Erythematosus National Assessment 
      version of the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) and 
      physician's global assessment (PGA). Levels of these markers were correlated with 
      SLEDAI scores, and their sensitivity and specificity for clinical SLE activity 
      were determined. RESULTS: A total of 94 SLE patients (98% women, mean +/- SD age 
      28.7 +/- 9.4 years, mean +/- SD disease duration 5.4 +/- 5.0 years) and 49 healthy 
      controls were studied. Fifty-two patients had clinically active SLE (defined as 
      SLEDAI score >/=6 or having a flare). The serum concentrations of Axl, ferritin, 
      IGFBP-2, and TNFRII were significantly higher in patients with active SLE than in 
      those with inactive SLE or in controls. The levels of these markers correlated 
      strongly and significantly with anti-double stranded DNA (anti-dsDNA), C3, and 
      clinical SLEDAI and PGA scores. These markers were more specific, but less 
      sensitive, in detecting concurrent SLE activity than elevated anti-dsDNA or 
      depressed C3. Levels of Axl, TNFRII, and IGFBP-2, but not ferritin, could 
      differentiate active renal from active nonrenal or inactive SLE. The specificity 
      of Axl and IGFBP-2 for concurrent active lupus nephritis was higher than 
      anti-dsDNA or C3. CONCLUSION: Serum proteomic markers are potentially useful for 
      diagnosing SLE and monitoring disease activity. The performance of Axl and 
      IGFBP-2 in lupus nephritis should be further explored in a longitudinal cohort of 
      SLE patients.
CI  - (c) 2016, American College of Rheumatology.
FAU - Mok, Chi Chiu
AU  - Mok CC
AD  - Tuen Mun Hospital, Hong Kong, China.
FAU - Ding, Hui Hua
AU  - Ding HH
AD  - University of Houston, Houston, Texas.
FAU - Kharboutli, Marwa
AU  - Kharboutli M
AD  - University of Houston, Houston, Texas.
FAU - Mohan, Chandra
AU  - Mohan C
AD  - University of Houston, Houston, Texas.
LA  - eng
GR  - R01 DK081872/DK/NIDDK NIH HHS/United States
PT  - Journal Article
DEP - 20160728
PL  - United States
TA  - Arthritis Care Res (Hoboken)
JT  - Arthritis care & research
JID - 101518086
RN  - 0 (Biomarkers)
RN  - 0 (IGFBP2 protein, human)
RN  - 0 (Insulin-Like Growth Factor Binding Protein 2)
RN  - 0 (Proto-Oncogene Proteins)
RN  - 0 (Receptors, Tumor Necrosis Factor, Type II)
RN  - 0 (TNFRSF1B protein, human)
RN  - 9007-73-2 (Ferritins)
RN  - EC 2.7.10.1 (Receptor Protein-Tyrosine Kinases)
RN  - 0 (Axl Receptor Tyrosine Kinase)
RN  - 0 (AXL protein, human)
SB  - IM
MH  - Adult
MH  - Biomarkers/*blood
MH  - Female
MH  - Ferritins/*blood
MH  - High-Throughput Screening Assays
MH  - Humans
MH  - Insulin-Like Growth Factor Binding Protein 2/*blood
MH  - Lupus Erythematosus, Systemic/*blood/diagnosis
MH  - Male
MH  - Protein Array Analysis
MH  - Proto-Oncogene Proteins/*blood
MH  - Receptor Protein-Tyrosine Kinases/*blood
MH  - Receptors, Tumor Necrosis Factor, Type II/*blood
MH  - Sensitivity and Specificity
MH  - Axl Receptor Tyrosine Kinase
PMC - PMC5441892
MID - NIHMS854210
EDAT- 2016/01/11 06:00
MHDA- 2017/07/20 06:00
PMCR- 2017/09/01
CRDT- 2016/01/11 06:00
PHST- 2015/08/15 00:00 [received]
PHST- 2015/12/14 00:00 [revised]
PHST- 2016/01/05 00:00 [accepted]
PHST- 2016/01/11 06:00 [entrez]
PHST- 2016/01/11 06:00 [pubmed]
PHST- 2017/07/20 06:00 [medline]
PHST- 2017/09/01 00:00 [pmc-release]
AID - 10.1002/acr.22835 [doi]
PST - ppublish
SO  - Arthritis Care Res (Hoboken). 2016 Sep;68(9):1303-9. doi: 10.1002/acr.22835. Epub 
      2016 Jul 28.